Walgreens Boots Alliance Flis 24% On Better Than Expected Q1 Earnings, Sticks To Annual Profit Forecast
Walgreens Boots Alliance Flis 24% On Better Than Expected Q1 Earnings, Sticks To Annual Profit Forecast
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.On Friday, $Walgreens Boots Alliance (WBA.US)$ reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the consensus of $37.28 billion, reflecting sales growth across all segments.
星期五， $沃尔格林-联合博姿 (WBA.US)$ 报告第一季度销售额为394.6亿美元，同比增长7.5%（以固定货币计算同比增长6.9%），超过372.8亿美元的预期，反映了所有板块的销售增长。
Adjusted operating income was $593 million compared to adjusted operating income of $687 million in the year-ago quarter, reflecting lower U.S. retail sales and lapping prior year sale-leaseback gains, partly offset by cost savings initiatives and growth in the U.S. Healthcare segment.
调整后的营业收入为59300万美元，而去年同期的调整后营业收入为68700万美元，反映出美国零售销售下降以及去年销售-租回收益的对比 effect，部分被成本节约措施和美国医疗保健板块的增长抵消。
Adjusted EPS was $0.51, down from $0.66 a year ago, beating the consensus of $0.37, according to data from Benzinga Pro.
调整后的每股收益为0.51美元，低于去年同期的0.66美元，但超出0.37美元的预期，根据Benzinga Pro的数据。
The U.S. Retail Pharmacy segment sales reached $30.9 billion, up 6.6%. Comparable sales increased 8.5%.
美国零售药房板块的销售额达到309亿美元，增长6.6%。可比销售增长8.5%。
Pharmacy sales increased by 10.4%, and comparable pharmacy sales increased by 12.7%, driven by higher branded drug inflation and prescription volume.
药房销售增长了10.4%，可比药房销售增长了12.7%，主要受品牌药品通胀和处方成交量增加的推动。
Comparable prescriptions increased by 2.3%, and prescriptions excluding immunizations increased by 3.5% compared to a year ago.
可比处方增加了2.3%，不包括免疫接种的处方则增加了3.5%，与去年相比。
Total prescriptions filled in the quarter, including immunizations, increased 1.5% to 316.3 million.
包括免疫接种在内的季度内总处方量增加了1.5%，达31630万。
Retail sales decreased 6.2%, and comparable retail sales decreased 4.6% compared with the year-ago quarter, mirroring a weaker cough cold flu season and lower sales in discretionary categories.
零售销售下降了6.2%，可比零售销售较去年同期下降了4.6%，反映出寒冷流感季节较弱以及可自由支配类商品销售降低。
The U.S. Healthcare segment's sales were $2.2 billion. VillageMD sales increased 9%, CareCentrix sales increased 16%, and Shields sales rose 30%.
美国医疗保健部门的销售额为22亿。VillageMD的销售额增长了9%，CareCentrix的销售额增长了16%，Shields的销售额增长了30%。
Walgreens Boots Alliance maintains fiscal 2025 adjusted EPS guidance of $1.40 – $1.80 versus the consensus of $1.52.
沃尔格林-联合博姿维持2025财年的每股收益调整指引为1.40美元至1.80美元，而市场共识为1.52美元。
The company expects growth in U.S. Healthcare and International offset by pressure in U.S. Retail Pharmacy largely driven by weaker retail front end performance.
公司预计美国医疗保健和国际业务的增长将被美国零售药房的压力所抵消，后者主要受到零售前端表现疲弱的影响。
